Search - tctmd.com

Displaying 21 - 40 of 67

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

Caitlin E. Cox

September 18, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Advertisement

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Less Is More: Lp(a) Much More Atherogenic Than LDL

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Top General Cardiology and Prevention News of 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content